Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback